The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.

The company said it expects this restructuring plan to result in its quarterly cash flow breaking even by the second half of next year.

During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

NEW YORK – Sensorion on Monday said that by year end it expects to complete dosing the first cohort of pediatric patients with congenital hearing loss with its gene therapy candidate SENS-501 in the ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...